Marjac, Thanks for the explanation. I’d be shocked and devastated to see Dyke or Reyna on the appeal. It’s mathematically possible but the odds of it happening randomly is very low. How could the same two judges that issued rule 36 in two recent cases involving AMRN and Hikma be allowed preside over a third case with the same parties.? They would obviously be biased against AMRN from the get go. It seems a mechanism should be in place to prevent this from happening, or to allow for AMRN to object and request a new panel, based on potential bias and the egregious abuse of rule 36 in two prior cases. On the bright side, I’m glad we have one more chance at Hikma and that the two cases are separate. I think the bigger and more important case is the one against HN as payers/pharmacies are the biggest and most obvious infringers.